Skip to main content

Table 1 Overview of the assays used in this study to assess extracellular matrix turnover

From: Accelerated extracellular matrix turnover during exacerbations of COPD

Assay Target Detection range (ng/ml) Intra-and inter-assay variation (%) Reference level (ng/ml), mean (SD) References
C3M Collagen type III degraded by MMPs 5.52–177 3.4 and 9.8 15.3 (3.8) [28]
C4M Collagen type IV degraded by MMPs 22.8–748 4.2 and 18.5 55.4 (17.8) [29]
C6M Collagen type VI degraded by MMPs 4.88–420 8.0 and 11.0 8.85 (5.1) [30]
ELM7 Elastin degraded by MMP-7 1.16–36.6 8.1 and 9.1 2.23 (0.74) Preliminary data
EL-NE Elastin degraded by neutrophil elastase 1.76–167 8.6 and 12.9 4.09 (2.24) [31]
VCANM Versican degraded by MMPs 0.78–7.13 3.0 and 7.6 1.20 (0.23) [32]
Pro-C3 Collagen type III propeptide (N-terminal) 5.32–96.4 6.5 and 12.4 12.3 (4.4) [33]
P4NP 7S Collagen type IV 7S domain 32.9–3460 9.4 and 14.2 263 (91.3) [34]
Pro-C6 Collagen type VI C5 domain 0.30–117 4.8 and 15.2 4.37 (0.69) Preliminary data
  1. The reference level was provided by the manufacturer (Nordic Bioscience) and refers to the biomarker level of a healthy population in the relevant matrix, i.e. serum (C3M, C4M, Pro-C3, P4NP 7S, ELM7, EL-NE) or plasma (C6M, Pro-C6, VCANM). SD, standard deviation; MMP, matrix metalloproteinase